NCT04302025 2026-03-06
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Genentech, Inc.
Phase 2 Recruiting
Clinical Trials
40 trialsNCT01909453 2026-02-27
COLUMBUS
Pfizer
Phase 3 Completed
NCT03768063 2026-01-29
IMbrella B
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT06008119 2025-09-18
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Shanghai Kechow Pharma, Inc.
Phase 3 Recruiting
NCT02908672 2025-07-20
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
Hoffmann-La Roche
Phase 3 Completed
NCT01378975 2025-06-25
A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases
Hoffmann-La Roche
Phase 2 Completed
NCT02091141 2024-07-23
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
Genentech, Inc.
Phase 2 Completed
NCT03625141 2024-04-11
A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases
Hoffmann-La Roche
Phase 2 Completed
NCT03781219 2023-05-31
A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation
Shanghai Kechow Pharma, Inc.
Phase 1 Unknown
NCT05233332 2023-05-31
mCRC
Shanghai Kechow Pharma, Inc.
Phase 2 Unknown
NCT05263453 2023-05-31
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
Shanghai Kechow Pharma, Inc.
Phase 2 Unknown
NCT01689519 2022-05-02
coBRIM
Hoffmann-La Roche
Phase 3 Completed
NCT01683188 2021-02-01
PROCLIVITY01
Clinigen, Inc.
Phase 4 Terminated
NCT01739764 2021-01-07
An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol
Hoffmann-La Roche
Phase 4 Completed
NCT01656642 2020-07-21
A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
Genentech, Inc.
Phase 1 Completed
NCT02608034 2020-02-12
A Study to Investigate the Effect of Itraconazole and Rifampin on Pharmacokinetics (PK) of Vemurafenib at Steady State
Genentech, Inc.
Phase 1 Completed
NCT01898585 2020-01-07
An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma
Hoffmann-La Roche
Phase 4 Completed
NCT02768207 2019-08-28
A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma
Hoffmann-La Roche
Phase 2 Completed
NCT01271803 2019-07-29
A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma
Hoffmann-La Roche
Phase 1 Completed
NCT01667419 2019-07-23
BRIM8
Hoffmann-La Roche
Phase 3 Completed
NCT01910181 2019-05-29
A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma
Hoffmann-La Roche
Phase 1 Completed
NCT03139513 2019-01-22
MELANIS
Hoffmann-La Roche
Completed
NCT01673854 2018-07-24
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
Bristol-Myers Squibb
Phase 2 Completed
NCT01616199 2018-05-16
Study of PX-866 and Vemurafenib in Patients With Advanced Melanoma
Seagen Inc.
Phase 1/2 Terminated
NCT01767623 2018-02-13
A Study of The Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation-Positive Cancer Participants
Hoffmann-La Roche
Phase 1 Completed
NCT02441465 2017-11-14
Bioavailability Study of Vemurafenib in Participants With BRAF^V600 Mutation-Positive Malignancies
Hoffmann-La Roche
Phase 1 Completed
NCT02456701 2017-09-05
Enhancing Radioiodine Incorporation Into BRAF Mutant Thyroid Cancers With the Combination of Vemurafenib and KTN3379
Celldex Therapeutics
Phase 1 Completed
NCT00405587 2017-08-22
Safety Study of PLX4032 in Patients With Solid Tumors
Plexxikon
Phase 1 Completed
NCT00949702 2017-07-25
A Study of Vemurafenib in Previously Treated Patients With Metastatic Melanoma
Hoffmann-La Roche
Phase 2 Completed
NCT01586195 2017-05-25
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
Genentech, Inc.
Phase 2 Terminated
NCT01765543 2016-12-15
A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)
Hoffmann-La Roche
Phase 1 Completed
NCT01849666 2016-11-02
A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Hoffmann-La Roche
Phase 1 Completed
NCT01851824 2016-11-02
A Study of the Effect of Vemurafenib on the Pharmacokinetics of Acenocoumarol in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy
Hoffmann-La Roche
Phase 1 Completed
NCT01974258 2016-11-02
Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients
Hoffmann-La Roche
Phase 1 Withdrawn
NCT01519323 2016-10-10
BRIM-P: A Study of Vemurafenib in Pediatric Patients With Stage IIIC or Stage IV Melanoma Harboring BRAFV600 Mutations
Hoffmann-La Roche
Phase 1 Terminated
NCT01006980 2016-09-28
A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
Hoffmann-La Roche
Phase 3 Completed
NCT01286753 2016-09-07
A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation
Hoffmann-La Roche
Phase 2 Completed
NCT01765569 2015-09-23
A Pharmacokinetics Study to Investigate the Effect of Vemurafenib on Digoxin in Patients With BRAFV600 Mutation-Positive Metastatic Melanoma
Hoffmann-La Roche
Phase 1 Completed
NCT01673737 2015-04-10
A Phase I/Ib Trial for the Evaluation of SAR260301 in Monotherapy or in Combination With Vemurafenib in Patients With Various Advanced Cancer
Sanofi
Phase 1 Completed
NCT01400451 2015-01-01
Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)
Bristol-Myers Squibb
Phase 1 Terminated